GoodRx Holdings just rose 13.8% to US$3.72, and the move reflects both emotion and the reported numbers. Coming into today, the stock had already climbed steadily over the past month, so expectations were not low. What really caught traders’ attention was a Q2 revenue figure of about US$200.4m paired with adjusted EBITDA of US$63.7m, which put profitability in sharper focus.

The market is now treating this quarter as a referendum on whether GoodRx’s profit profile can justify its rich trailing P/E multiple. Today’s spike is the opening argument, not the full verdict.

Love GoodRx Holdings’ sharp focus on profitability but want stocks with similar fundamentals that may appear less sensitive to rich P/E debates? Check out our hand picked 50 high quality undervalued stocks for ideas that combine earnings power with balance sheet strength.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$200.4m vs. US$203.1m (slight decline year on year)
• Net Income, Q2 2026 vs. Q2 2025: US$8.5m vs. US$12.8m (decline year on year)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.025 vs. US$0.036 (decline year on year)
• Adjusted EBITDA, Q2 2026: US$63.7m, with no Q2 2025 figure disclosed here (the 31.8% margin highlights the current profitability focus at GoodRx Holdings)

Prefer clean charts over scrolling through pages of raw earnings figures and margins for GoodRx Holdings? View the full financial picture, including how its valuation compares with its profit profile, in our visual company report for GoodRx Holdings.

GoodRx’s Profit Story Meets Concrete Subscription Milestones

The bullish view around GoodRx centers on subscriptions and pharmacy integrations turning a one time coupon user into a predictable, higher margin customer. Q2 gives some real proof points. Subscription revenue of US$28.5m with 39% year on year growth and a 14% rise in subscription plans shows that more users are moving into recurring products. Management has made Companion the main call to action across GoodRx and is backing that up with a bundle that includes 200 free generics, low cost drugs and telehealth. This directly supports the narrative of deeper engagement and better retention.

Pharma Direct, at US$61.6m and growing faster than the rest of the business, signals that manufacturers are increasingly using GoodRx as a consumer access channel. Together with a 31.8% adjusted EBITDA margin, these milestones go some way toward validating the margin focused bull case, even as legacy prescription transactions soften.

Access the analyst estimates for GoodRx Holdings to see where the consensus models start to diverge on GoodRx Holdings, and whether the calm surface around today’s price hides a very different picture for the next few years.

GoodRx Bear Case: Volume Slippage Still Hard To Ignore

The bearish worry around GoodRx is that its prescription coupon model loses relevance as partners change economics and users migrate to other channels, leaving revenue concentrated in a narrower set of programs. Q2 does not fully put that concern to bed. Prescription transactions revenue sits at US$106.4m while monthly active consumers fell 12% year on year to 5.0m. Management frames this as a planned shift into subscriptions; however, the core traffic metric that underpinned the original thesis is moving the wrong way.

Bears also focus on execution risk in new revenue streams. Pharma Direct revenue of US$61.6m and subscription revenue of US$28.5m show real traction, but management is still reviewing which KPIs to disclose and acknowledges the business is mid transition. That lack of clearer unit economics and new metrics means some milestones on transparency and durability are still missing.

After a margin step down and shifting revenue mix at GoodRx Holdings, review the independent risk analysis for GoodRx Holdings which shows 2 important warning signs to identify any other structural pressure points.

Take Control of Your Next Move

If the mix of rising subscription traction and softer prescription volumes at GoodRx Holdings has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and wait for conditions that suit your strategy. Once you are invested, use the Portfolio Command Center to keep on top of GoodRx Holdings and the rest of your holdings with focused alerts that cut out background noise. For the longer journey, tap into the Community to see how other investors are thinking about the same risks and milestones. This helps you spot potential catalysts or pressure points early and stay a step ahead of the market.

Seeking Alternatives Beyond GoodRx Holdings?

Fresh stock ideas can move from quiet accumulation to breakout momentum before most investors even notice. Use these under the radar lists while it matters and get in early.

• Chase stronger balance sheet momentum by reviewing a curated list of solid balance sheet and fundamentals stocks (49 results) that filters for companies with healthier finances and room to fund growth without constant dilution.
• Ride potential income steadying your portfolio by scanning a focused group of 9 dividend fortresses that prioritize durability alongside headline yield so you are not caught chasing yield traps.
• Target future facing infrastructure themes through a hand picked pool of 36 power grid technology and infrastructure stocks before capital floods in and squeezes the easier entry points.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.